Mandate

Vinge advises Hexatronic in conjunction with the acquisition of Opternus GmbH

October 25, 2018 M&A

Vinge has advised Hexatronic Group AB (publ), listed on Nasdaq Stockholm mid‑cap, in connection with the acquisition of the entire share capital in the German fibre optic company Opternus GmbH.

Opternus is the market leader within sales and service of fibre welds and measurement equipment on the fast growing German market for fibre optic equipment. The purchase price amounts to MEUR 10 on a cash and debt free basis as well as an earnout of a maximum of MEUR 2.7. The purchase price is paid with MEUR 9 in cash and MEUR 1 as newly issued shares in Hexatronic. Closing, which is subject to customary conditions, is anticipated shortly.

Vinge’s team primarily consisted of responsible partner Anders Strid, Wibeke Sorling and corporate assistant Camilla Andersson. In addition, ALP Rechtsanwälte through Dr. Sven Oksaar acted as local counsel.
 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026